ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $31.44M rose 27.6% year over year, ahead of the -0.1% change in trailing-twelve-month research & development. Sequentially, it rose 21.6% from the prior quarter. Over 3 fiscal years it compounded at +21.2% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +27.6% holds above the trailing-twelve-month pace of -0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 109.82M USD
- Year-over-year change
- -3.7%
- 4-year CAGR
- +17.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.82M | -3.7% |
| FY2024 | 2024-12-31 | 114.07M | +33.9% |
| FY2023 | 2023-12-31 | 85.17M | +38.1% |
| FY2022 | 2022-12-31 | 61.68M | +8.5% |
| FY2021 | 2021-12-31 | 56.86M | — |
Research & Development vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 research & development of $116.62M is the 7th highest of the 11 companies compared; the peer median is $125.66M.
- Its year-over-year change of -0.1% is the 10th highest of 11, against a peer median of +22.6%.
- Over three fiscal years its annual growth of +21.2% compares with a peer median of +30.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $255.99M | +3.7% | +29.7% | 117.9% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $127.65M | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $111.3M | +26.9% | +33.8% | — | |
| LTM Sep 2026 | $98.95M | +16.0% | +40.4% | — | |
| LTM Mar 2026 | $37.44M | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $18.58M | +33.3% | +11.1% | — | |
| Peer median (excluding ORIC) | $125.66M | +22.6% | +30.6% | 117.9% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.